FluidAI Medical announces an acquisition deal with Emmetros Limited
Stream Inara™ is part of FluidAI's Recovery Intelligence and Surgical Excellence (RISE) Program, a quality improvement program designed to improve surgical care and enable Enhanced Recovery After Surgery (ERAS) protocols. RISE spans the entire surgical journey and includes Stream Care™, an AI-assisted Surgical Expert Suite; the FDA-cleared Origin™ monitoring device; and Stream Inara™ for post-discharge patient education and engagement at home. The RISE program enables the adoption of tailored, data-driven solutions that align with each institution's clinical goals.
Stream Inara™ extends surgical care beyond the hospital, serving as a digital management tool before surgery and after patients return home. The platform monitors patients after discharge, collects patient-reported outcomes, and provides personalized education, continuous engagement, and 24/7 support to help patients adhere to care plans and recover safely. Integrating Stream Inara™ into FluidAI's RISE Program is designed to support earlier discharge. As a result, patients can recover at home, hospitals can increase patient throughput and optimize bed use, and clinicians can remain confident knowing their patients stay connected throughout recovery.
"I could not be more pleased about this acquisition by FluidAI, which represents the best possible next chapter for our technology and our mission," said Emmetros CEO and Co-Founder
"Emmetros has always been dedicated to patient-centric care. Focused on solutions that empower patients and care providers, they have set the standard for how we can engage and communicate with patients," said
About FluidAI Medical
FluidAI Medical is a Canadian medical technology company founded in 2014 and dedicated to advancing data-driven care, using real-time information to transform surgical care at all points in a patient's journey. FluidAI Medical specializes in building monitoring and digital platforms that turn previously untapped data into actionable insights for clinicians, enabling earlier intervention, more precise decision-making, and improved patient outcomes.
FluidAI Medical's product portfolio includes Origin™, an FDA-cleared hardware device that captures continuous biochemical signals directly from surgical drainage fluid; Stream Care™, an AI-driven surgical expert suite that identifies patients at risk of complications; Stream Inara™, a patient education and engagement platform; and Stream CMx™, a clinical documentation and generation tool.
Follow FluidAI Medical on LinkedIn for the latest news or visit the FluidAI Medical website for more information.
About Emmetros Limited
Founded in 2014, Emmetros is a leader in inclusive and intuitive healthcare technology. Its flagship product, SparxConnect, is a secure and highly customizable engagement and collaboration platform that enables home, residential, and surgical care providers to deliver exceptional personalized care experiences to patients, families, and the teams who care for them.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fluidai-medical-announces-an-acquisition-deal-with-emmetros-limited-302626855.html
SOURCE Fluid AI Medical
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CU SoCal Donates More Than $340,000 to Strengthen Southern California Communities
- Institute for Portfolio Alternatives Announces 2027 Board of Directors
- Exclusive: National Vision CEO on traffic, ticket growth and the digital shift
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share